JUN 01, 2022 11:12 AM PDT

Personalized Cancer Vaccine Showing Promise in Treating Melanoma and Ovarian Cancer

WRITTEN BY: Zoe Michaud

Cancer vaccines have been around for decades, but a unique neoantigen vaccine called NeoVax is giving researchers new hope that this technology could soon be more widely available. Since cancer cells are unique from person to person, personalized medicine is especially promising for cancer treatments. For NeoVax, a patient’s own cancer cells are harvested to create the personalized vaccine.

From the cancer cells, small protein fragments called “peptides” are mixed with a compound called poly-ICLC that activates the immune system. Poly-ICLC works by binding to proteins on the surface of certain immune cells, making it appear as if a virus is present and in turn triggering the immune system to attack the cancer cells specific to the patient’s body. When the personalized vaccine is administered, the immune system creates anti-tumor T-cells, a type of white blood cell that fights inflammatory and autoimmune diseases.

In one study, the researchers administered the personalized vaccines to eight high-risk melanoma patients enrolled in a clinical trial and found that the immune response triggered by the vaccine lasted for years. After four years, all eight patients remained alive, and six had no evidence of active disease.

The NeoVax vaccine is also being tested for safety and feasibility in Ovarian cancer. Researchers are hopeful that this technology will be effective in treating Ovarian cancer patients given the complexity of this type of cancer.

To create the personalized NeoVax vaccine, researchers must first determine which mutations are present in a patient’s tumor. This involves sequencing the tumor’s DNA and analyzing those results. Next, the researchers must manufacture a vaccine for the patient. Manufacturing the vaccines are still costly and time consuming. Still, the researchers hope that with the right technology, costs can be reduced, and the vaccine can be manufactured within a few days instead of the few weeks that it currently takes.

Sources: Nature Medicine, Cancer Discovery, Defense Technical Information Center

About the Author
Biology
Zoe (she/her) is a science writer and a scientist working in genomics. She received her B.S. from the University of Connecticut with a focus in Evolutionary Biology. At Labroots, she focuses on writing scientific content related to clinical research and diagnostics.
You May Also Like
AUG 21, 2022
Drug Discovery & Development
Eczema Drug Helps Increase Covid-19 Survival Rates, Clinical Study Suggests
AUG 21, 2022
Eczema Drug Helps Increase Covid-19 Survival Rates, Clinical Study Suggests
In a recent study published in Open Forum Infectious Diseases, a clinical study led by the University of Virginia (UVA) ...
SEP 06, 2022
Clinical & Molecular DX
Low Testosterone May Increase Risk of COVID-19 Hospitalization For Men
SEP 06, 2022
Low Testosterone May Increase Risk of COVID-19 Hospitalization For Men
Low testosterone in men, also referred to as male hypogonadism, can impact health and development in a multitude of ways ...
SEP 13, 2022
Clinical & Molecular DX
Stress During Pregnancy Linked to Negative Emotions in Infants
SEP 13, 2022
Stress During Pregnancy Linked to Negative Emotions in Infants
Stress during pregnancy can have long lasting effects and can impact emotional and physical development in children. Pas ...
SEP 10, 2022
Health & Medicine
What You See Isn't What You Get - The Science of Perception
SEP 10, 2022
What You See Isn't What You Get - The Science of Perception
People are different, with different backgrounds, different experiences, and different lives. So, it may come as no surp ...
SEP 12, 2022
Cancer
Novel Method to Detect Cancer with a Blood Screen Demonstrates Feasibility
SEP 12, 2022
Novel Method to Detect Cancer with a Blood Screen Demonstrates Feasibility
Early detection of cancer benefits patients with almost all cancer types.  Late-stage tumors remain more difficult ...
SEP 28, 2022
Health & Medicine
After COVID-19 Infection, Risk of Blood Clots Could Remain for a Year
SEP 28, 2022
After COVID-19 Infection, Risk of Blood Clots Could Remain for a Year
Blood clots are a known risk from a COVID-19 infection. Blood clots are clumps of blood that naturally form to help the ...
Loading Comments...